Aberrant activation of Wnt/b-catenin canonical signaling is observed in multiple malignant tumors, and is recognized as an attractive therapeutic target for molecular targeted drugs. This signaling pathway is also involved in maintaining pluripotency in adult stem cells. Therefore, lowering potential stem cell toxicity is a key factor for the development of a Wnt/b-catenin signaling inhibitor. Here, we show Wnt/b-catenin pathway inhibitors with low toxicity, identied through phenotype-based screening using zebraˆsh embryos. Artiˆcial activation of the Wnt/b-catenin pathway in fertilized eggs, which are often considered the``ultimate stem cells'', results in an``eyeless'' phenotype in zebraˆsh embryos. Screening for compounds that rescue this``eyeless'' phenotype and have no eŠects on normal embryogenesis could help us identify Wnt/b-catenin pathway inhibitors with minimal stem cell toxicities, at least at a concentration that suppresses aberrant signaling. Chemical suppressors of the``eyeless'' phenotype include novel and known compounds with diŠerent modes of action. Some of these compounds diminish the activation of crosstalk between other signaling pathways and the Wnt/b-catenin pathway. These inhibitors reduced tumor growth in ApcMin/＋ mice and did not show apparent toxicities. Thus, our screening for chemical suppressors of the``eyeless'' phenotype allowed us to successfully identify inhibitors for the Wnt/b-catenin pathway with low toxicity.

